Epitalon: what the human evidence actually is, and who produced it

Epitalon’s human evidence rests on three indexed papers, all co-authored by Vladimir Khavinson, all run by his St Petersburg institute or its partner in Kiev, and all testing epithalamin — a crude extract of animal pineal glands — rather than the synthetic four-amino-acid peptide sold today. Those papers report lower mortality in elderly patients; none used a placebo, none was blinded, and none reports the figures behind its headline. The laboratory case is the stronger one: cell work showing epitalon switches on telomerase and lengthens telomeres, independently replicated in 2025 by a group with no link to the original lab.

What it is

Epitalon (also spelled epithalon) is a tetrapeptide: alanine, glutamic acid, aspartic acid and glycine, usually written AEDG. It was designed at the St Petersburg Institute of Bioregulation and Gerontology, the group led by Vladimir Khavinson, as a synthetic stand-in for epithalamin, a polypeptide mixture extracted from animal pineal glands. Khavinson’s theory of “peptide bioregulation” holds that very short peptides from a given organ can enter cells, bind DNA and nudge the genes of that organ back towards a younger pattern. That is a hypothesis from one school of research, and its reach outside that school is narrow.

Two mechanisms get quoted most often. The first is telomerase, the enzyme that rebuilds the protective caps (telomeres) at the ends of chromosomes. The second is the pineal gland’s melatonin rhythm, which flattens with age. Both are mechanism theories supported mainly by cell and animal work, described below.

The human evidence

Here is the precise version of the claim you will see repeated online. There are three indexed papers reporting outcomes in older people, all co-authored by Khavinson, all run by his St Petersburg institute or its partner, the Institute of Gerontology in Kiev, and all using epithalamin, the extract.

The Kiev coronary study. A 2006 paper describes a 12-year randomised study of elderly patients with coronary disease and “accelerated ageing” of the cardiovascular system [7]. The treated group received repeated courses of epithalamin on top of standard care. The abstract reports that by 12 years, deaths were 28% lower than in the control group, cardiovascular deaths were halved, and exercise tolerance and “functional age” improved [7]. It gives no group sizes, no method of randomisation and no confidence intervals.

The 15-year follow-up. A 2011 paper from the same authors describes 39 coronary patients given six courses of epithalamin over three years plus standard therapy, against 40 who received standard therapy alone, followed for 15 years [8]. It reports slower cardiovascular ageing, a normalised melatonin rhythm and “significantly lower mortality” [8]. The English abstract gives no mortality figures. Its title, oddly, describes the product as a peptide “from the pituitary gland”, while the abstract’s own closing sentence calls it a preparation from the pineal gland. The two papers share authors, an institute and a design, and may well describe overlapping patients; neither abstract says so either way.

The 266-person cohort. A 2003 paper pooled 266 people over 60 treated with thymalin (a thymus extract), epithalamin, or both, and followed them for six to eight years [9]. It reports mortality 1.6 to 1.8 times lower with epithalamin alone and 2.5 times lower with both extracts, against controls. It is described as a clinical assessment rather than a randomised trial, and the abstract does not say how controls were chosen.

Side by side, the three papers look like this.

None of the three used synthetic AEDG. None reports a placebo or blinding. All three list Khavinson as an author.

What these papers would need to convince us is missing: blinding, a placebo, a registered protocol, reported dropouts, and replication by anyone outside the network. Survival differences of this size in small open-label studies of older people can come from how patients were allocated and followed. So we treat them as a lead rather than a result — a lead for epithalamin, and one that does not yet extend to the synthetic peptide.

What the lab and animal work suggests

Telomerase in cells. In 2003, Khavinson’s group reported that adding epitalon to cultured human fetal fibroblasts, which normally lack telomerase, switched on the enzyme’s catalytic subunit and lengthened telomeres [1]. A follow-up said treated fetal lung fibroblasts, which stopped dividing at passage 34, went on to reach passage 44, about ten extra divisions [2]. These are short papers and the telomerase finding sat unreplicated for two decades.

In 2025 a group at Brunel University London, with no link to Khavinson, tested it again [3]. In normal human epithelial cells and fibroblasts, epitalon lengthened telomeres in a dose-dependent way through more telomerase activity. In two breast cancer cell lines it also lengthened telomeres, mainly through a different route called ALT (alternative lengthening of telomeres) [3]. That is the most useful independent result on epitalon so far. It is still a cell study, and the cancer-cell finding cuts both ways, as the safety section explains.

Lifespan and tumours in mice. The best-known animal study gave female SHR mice monthly five-day courses of epitalon from three months of age until death, 54 mice per group [4]. Average lifespan did not change. The longest-lived 10% survived 13.3% longer, maximum lifespan was 12.3% longer, chromosome damage in bone marrow fell by 17.1%, and leukaemia was six times less common, though total tumour incidence was unchanged [4]. In mice bred to develop HER-2/neu breast tumours, epitalon reduced the number and size of tumours and the size of lung metastases [5].

Melatonin in monkeys. In ageing female rhesus macaques, epitalon raised evening melatonin and restored a more normal daily cortisol rhythm [6]. The abstract gives no animal numbers.

Egg cells. A Chinese group, again independent, found that epitalon reduced oxidative damage in mouse eggs aged in a dish after ovulation [10].

A 2025 review from a Polish team pulled the field together and reached the same conclusion we did: the biological signals are interesting, but most of the evidence comes from a single research circle and much of it was published in Russian-language or low-visibility journals [11].

Safety and side effects reported

No published human study reports adverse events for synthetic epitalon, because no published human study of it exists to report them from. The mouse lifespan work found no toxicity with lifelong monthly courses [4], a reassuring result in mice at the doses used; human tolerability has not been measured.

The theoretical concern is telomerase itself. Most human cancers keep dividing by reactivating it, and a substance that switches it on in healthy cells raises an obvious question. The mouse tumour results point the other way [4,5], but the Brunel finding that epitalon lengthened telomeres in breast cancer cell lines, via ALT, is a reason for caution rather than comfort [3].

Product quality is a separate problem. Belgium’s public health institute identified epitalon in two illegal pharmaceutical preparations, marketed for cancer, old age and retinitis pigmentosa [12]. What is in an unregulated vial is unknown to the person using it.

Legal and regulatory status

Epitalon is not approved as a medicine by the MHRA, the FDA or the European Medicines Agency. In the US, the FDA placed it on its list of bulk substances for compounding that may present significant safety risks. The page, updated in April 2026, now lists epitalon among nominations withdrawn by the nominators, while still noting a potential risk of immune reactions from aggregation and peptide-related impurities, and that the agency lacks enough safety information to judge harm in humans [13]. Epitalon is not named on the WADA Prohibited List, but unapproved substances are banned for athletes under WADA’s S0 category, so competitors should assume it is prohibited [14].

What is still open

• Whether synthetic epitalon does anything measurable in people. No placebo-controlled trial of it has been published in an indexed journal that we could find.
• Whether the epithalamin survival results would hold up in a blinded, registered trial run by an independent group.
• How epitalon behaves in the body: absorption, half-life and tissue levels in humans are unpublished.
• Whether switching on telomerase in healthy tissue raises cancer risk over years of use.
• What people buying “epitalon” are actually getting.

What this means

Our position is that epitalon is a live question, and that this is the honest place to leave it. There is a real biological signal — a tetrapeptide that switches on telomerase and lengthens telomeres in human cells, confirmed in 2025 by a laboratory with no connection to the one that found it. What the field lacks is not plausibility but human evidence built to a standard we would apply to any other compound: a registered protocol, a placebo, blinded allocation and an independent site.

That gap is the story, and it is different from the marketing. The only human survival data come from three papers by a single research network, describing epithalamin rather than synthetic epitalon, without blinding, placebo or published mortality figures. That does not make the results false. It makes them a lead rather than a conclusion, which is why no reader today can know whether epitalon extends life, does nothing, or causes harm over years of use.

So our view is deliberately narrow, and we will defend it: epitalon has a credible mechanism and no human evidence we can act on, which is not the same as a peptide shown not to work. We think the fair response to this literature is curiosity, not dismissal — a twenty-year-old finding from one Russian circle has already been independently confirmed at the cell level, and the human question could follow if someone funds and registers the trial.

Until that trial exists, we would not use epitalon and would not recommend it. If you are weighing it anyway, the honest reading is that you are buying an unknown quantity from an unregulated supply, and the mechanism that makes it interesting — switching on telomerase — is the same one most cancers exploit.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.